
## Li-Xia Yang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/478759/publications.pdf Version: 2024-02-01



Ιι-Χιλ Υλης

#	Article	IF	CITATIONS
1	miR-221 Alleviates the Ox-LDL-Induced Macrophage Inflammatory Response via the Inhibition of DNMT3b-Mediated NCoR Promoter Methylation. Mediators of Inflammation, 2019, 2019, 1-15.	3.0	12
2	Randomized comparison of novel biodegradable polymer and durable polymerâ€coated cobaltâ€chromium sirolimusâ€eluting stents: Threeâ€Year Outcomes of the l‣OVEâ€IT 2 Trial. Catheterization and Cardiovascular Interventions, 2018, 91, 608-616.	1.7	9
3	The feedback loop of "EMMPRIN/NF-κB―worsens atherosclerotic plaque via suppressing autophagy in macrophage. Journal of Molecular and Cellular Cardiology, 2018, 114, 129-140.	1.9	8
4	Omegaâ€6 fatty acids downâ€regulate matrix metalloproteinase expression in a coronary heart diseaseâ€induced rat model. International Journal of Experimental Pathology, 2018, 99, 210-217.	1.3	4
5	TRIF Regulates BIC/miR-155 via the ERK Signaling Pathway to Control the ox-LDL-Induced Macrophage Inflammatory Response. Journal of Immunology Research, 2018, 2018, 1-11.	2.2	10
6	Ca 2+ Entry Through Reverse Mode Na + /Ca 2+ Exchanger Contributes to Store Operated Channel-Mediated Neointima Formation After Arterial Injury. Canadian Journal of Cardiology, 2018, 34, 791-799.	1.7	5
7	Five-year outcomes of ST-elevation myocardial infarction versus non-ST-elevation acute coronary syndrome treated with biodegradable polymer-coated sirolimus-eluting stents: Insights from the CREATE trial. Journal of Cardiology, 2017, 69, 149-155.	1.9	8
8	Efficacy and safety of a biodegradable polymer Cobaltâ€Chromium sirolimusâ€eluting stent (EXCEL2) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials. Catheterization and Cardiovascular Interventions, 2017, 89, 512-519.	1.7	6
9	Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction. Experimental and Therapeutic Medicine, 2017, 13, 1578-1583.	1.8	3
10	Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway. Experimental and Therapeutic Medicine, 2017, 13, 835-844.	1.8	19
11	MicroRNA-99a inhibits insulin-induced proliferation, migration, dedifferentiation, and rapamycin resistance of vascular smooth muscle cells by inhibiting insulin-like growth factor-1 receptor and mammalian target of rapamycin. Biochemical and Biophysical Research Communications, 2017, 486, 414-422.	2.1	19
12	Ox-LDL-Induced MicroRNA-155 Promotes Autophagy in Human Endothelial Cells via Repressing the Rheb/ mTOR Pathway. Cellular Physiology and Biochemistry, 2017, 43, 1436-1448.	1.6	25
13	Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients. Minerva Cardiology and Angiology, 2017, 65, 111-118.	0.7	4
14	miR-155 Regulated Inflammation Response by the SOCS1-STAT3-PDCD4 Axis in Atherogenesis. Mediators of Inflammation, 2016, 2016, 1-14.	3.0	83
15	The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial. Catheterization and Cardiovascular Interventions, 2016, 87, 608-615.	1.7	10
16	NF-κB-Dependent Upregulation of NCX1 Induced by Angiotensin II Contributes to Calcium Influx in Rat Aortic Smooth Muscle Cells. Canadian Journal of Cardiology, 2016, 32, 1356.e11-1356.e20.	1.7	7
17	Identification of Rab6a as a New Target of microRNA-155 Involved in Regulating Lipopolysaccharide-Induced TNF Secretion. Inflammation, 2016, 39, 107-112.	3.8	9
18	MicroRNA-155 Promotes Atherosclerosis Inflammation via Targeting SOCS1. Cellular Physiology and Biochemistry, 2015, 36, 1371-1381.	1.6	95

LI-XIA YANG

#	Article	IF	CITATIONS
19	Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0141855.	2.5	3
20	A Randomized Comparison of Novel Biodegradable Polymer- and Durable Polymer–Coated Cobalt-Chromium Sirolimus-Eluting Stents. JACC: Cardiovascular Interventions, 2014, 7, 1352-1360.	2.9	39
21	MicroRNA-155 inhibits angiotensin II-induced vascular smooth muscle cell proliferation. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2014, 15, 109-116.	1.7	36
22	Changes in levels of angiotensin II and its receptors in a model of inverted stress-induced cardiomyopathy. European Journal of Medical Research, 2014, 19, 54.	2.2	3
23	Role of Krüppel-Like Factor 2 and Protease-Activated Receptor-1 in Vulnerable Plaques of ApoEâ^'/â^' Mice and Intervention With Statin. Canadian Journal of Cardiology, 2013, 29, 997-1005.	1.7	7
24	Atorvastatin Inhibits the 5-Lipoxygenase Pathway and Expression of CCL3 to Alleviate Atherosclerotic Lesions in Atherosclerotic ApoE Knockout Mice. Journal of Cardiovascular Pharmacology, 2013, 62, 205-211.	1.9	16
25	Angiotensin II induces extracellular matrix metalloproteinase inducer expression via an AT1R dependent pathway in aortic atherosclerotic plaque in apolipoprotein E knockout mice. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 67-75.	1.7	6
26	The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway. Inflammation Research, 2010, 59, 1033-1040.	4.0	7
27	Angiotensin II induces EMMPRIN expression in THP-1 macrophages via the NF-ήB pathway. Regulatory Peptides, 2010, 163, 88-95.	1.9	12
28	Role of TRPC1 and NF-κB in mediating angiotensin II-induced Ca2+ entry and endothelial hyperpermeability. Peptides, 2009, 30, 1368-1373.	2.4	15